Liang D C, Jiang C J
Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan, Republic of China.
Am J Hematol. 1991 Dec;38(4):267-70. doi: 10.1002/ajh.2830380403.
Epirubicin, a new anthracycline, was used in combination with cytosine arabinoside for the induction therapy of de novo acute nonlymphocytic leukemia in childhood. The treatment consisted of epirubicin 20 mg/m2/day for 3 days and cytosine arabinoside 100 mg/m2/day for 7 days. The treatment could be repeated every 3 weeks. Remission induction rate was 80% (20/25). Moreover, in 13 patients, the remissions were obtained after a single course. In general, the side effects of epirubicin and cytosine arabinoside were tolerable. However, the main causes of all the three deaths were infections. Our study suggests that epirubicin is acceptable and effective for the induction therapy for de novo acute nonlymphocytic leukemia in childhood.
表柔比星，一种新型蒽环类药物，与阿糖胞苷联合用于儿童初发急性非淋巴细胞白血病的诱导治疗。治疗方案为表柔比星20mg/m²/天，共3天，阿糖胞苷100mg/m²/天，共7天。每3周可重复进行该治疗。诱导缓解率为80%（20/25）。此外，13例患者在一个疗程后即获得缓解。总体而言，表柔比星和阿糖胞苷的副作用是可耐受的。然而，所有3例死亡的主要原因均为感染。我们的研究表明，表柔比星用于儿童初发急性非淋巴细胞白血病的诱导治疗是可接受且有效的。
